Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide vs conventional liver fasting before bariatric surgery in NAFLD
2020-000220-19Phase 4Completed
- Sponsor
- Verein zur Förderung von Wissenschaft und Forschung an der 1. Med. Abteilung
- Start
- Mar 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of liraglutide in obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Verein zur Förderung von Wissenschaft und Forschung an der 1. Med. Abteilung. Primary endpoint: Weight loss before bariatric surgery. Started Mar 2020; status: completed.
02
Drugs
03
Conditions
obesitymetabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on 2020-000220-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000220-19.